Category: M&A

Sanofi-Aventis to Buy Genzyme: The Wrap-Up

MEwens
Deconstructing the deal’s CVR; solving Genzyme’s manufacturing problems; avoiding the pitfalls of pharma-biotech deals; Viehbacher’s legacy.
Read more this great post here

Continued Read ...
Posted in Drugs, Biotech, M&A  

This Pharma-Biotech Marriage May Need to Pay Off Right Away

MEwens
For the French pharma company, the deal’s immediate benefits may be more important.
Read more this great post here

Continued Read ...
Posted in Drugs, Biotech, M&A  

A.M. Vitals: Sanofi-Aventis (Finally!) Will Buy Genzyme

MEwens
Also: results for a faster flu-vaccine production method; generic-drug makers want to pay user fees; malpractice law changes.
Read more this great post here

Continued Read ...

The Stats on Contingent Value Rights in Pharma Deals

MEwens
In only one recent case — OSI Pharmaceuticals’ 2003 purchase of Cell Pathways — is the result clear.
Read more this great post here

Continued Read ...
Posted in Drugs, M&A  

A.M. Vitals: Sanofi, Genzyme Still Working on Deal Price

MEwens
Also: President Obama’s 2012 budget due out today; new 3-D mammography system approved; retirees’ health benefits.
Read more this great post here

Continued Read ...

A.M. Vitals: Crucell’s Manufacturing Problems Resolved

Katherine Hobson
Also: One syphilis test has high false-positive rate; MannKind cuts workforce; ideal pain relief for labor?
Read more this great post here

Continued Read ...
Posted in Vaccines, M&A, pregnancy  

A.M. Vitals: Kindred to Buy RehabCare For About $900 Million

Katherine Hobson
Also: GSK reportedly settles Avandia claims; Avastin results for ovarian cancer; no defunding of health law in spending bill?
Read more this great post here

Continued Read ...

A.M. Vitals: Sanofi, Genzyme Hope to (Finally) Ink Deal This Week

MEwens
Also: alternatives to the individual mandate; formula-fed infants, solid food and obesity; pharmacy robberies.
Read more this great post here

Continued Read ...

A.M. Vitals: Sanofi May Pay $74 Per Share Up Front for Genzyme

MEwens
Also: the seriously ill worry about fate of the health law; Avastin side effects; lobbying to restore FSA eligibility.
Read more this great post here

Continued Read ...

A.M. Vitals: Genzyme and Sanofi Agree on Deal — In Principle

MEwens
Also: Roche gives back rights to a diabetes drug; drug shortages; a new kind of primary-care practice.
Read more this great post here

Continued Read ...
Posted in Drugs, Hospitals, M&A, Doctors  

Next Page »

 
Google
Web ekstrapalma.com

RSS Health Care Blog News